H
Hiroshi Kaito
Researcher at Kobe University
Publications - 94
Citations - 2271
Hiroshi Kaito is an academic researcher from Kobe University. The author has contributed to research in topics: Alport syndrome & Exon. The author has an hindex of 23, co-authored 87 publications receiving 1660 citations.
Papers
More filters
Journal ArticleDOI
Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Kazumoto Iijima,Mayumi Sako,Kandai Nozu,Rintaro Mori,Nao Tuchida,Koichi Kamei,Kenichiro Miura,Kunihiko Aya,Koichi Nakanishi,Yoshiyuki Ohtomo,Shori Takahashi,Ryojiro Tanaka,Hiroshi Kaito,Hidefumi Nakamura,Kenji Ishikura,Shuichi Ito,Yasuo Ohashi +16 more
TL;DR: Rituximab is an effective and safe treatment for childhood-onset, complicated FRNS and SDNS and the relapse-free period was the primary endpoint and safety endpoints were frequency and severity of adverse events.
Journal ArticleDOI
A review of clinical characteristics and genetic backgrounds in Alport syndrome
Kandai Nozu,Koichi Nakanishi,Yoshifusa Abe,Tomohiro Udagawa,Shinichi Okada,Takayuki Okamoto,Hiroshi Kaito,Katsuyoshi Kanemoto,Anna Kobayashi,Eriko Tanaka,Kazuki Tanaka,Taketsugu Hama,Rika Fujimaru,Saori Miwa,Tomohiko Yamamura,Natsusmi Yamamura,Tomoko Horinouchi,Shogo Minamikawa,Michio Nagata,Kazumoto Iijima +19 more
TL;DR: The diagnostic strategy, genotype–phenotype correlation, mechanisms of onset of milder phenotypes, and treatment of AS are reviewed, among others.
Journal ArticleDOI
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
Norishige Yoshikawa,Koichi Nakanishi,Mayumi Sako,Mari S. Oba,Rintaro Mori,Erika Ota,Kenji Ishikura,Hiroshi Hataya,Masataka Honda,Shuichi Ito,Yuko Shima,Hiroshi Kaito,Kandai Nozu,Hidefumi Nakamura,Takashi Igarashi,Yasuo Ohashi,Kazumoto Iijima +16 more
TL;DR: 2 months of initial prednisolone therapy for steroid-sensitive nephrotic syndrome, despite less prednisOLone exposure, is not inferior to 6 months ofInitial therapy in terms of time to onset of frequently relapsing neph rotic syndrome.
Journal ArticleDOI
Validity of the Oxford classification of IgA nephropathy in children.
Yuko Shima,Koichi Nakanishi,Taketsugu Hama,Hironobu Mukaiyama,Hiroko Togawa,Yuya Hashimura,Hiroshi Kaito,Mayumi Sako,Kazumoto Iijima,Norishige Yoshikawa +9 more
TL;DR: The Oxford classification of IgA nephropathy appears to be valid for predicting renal outcome in children, and crescents were important predictors of outcome.
Journal ArticleDOI
Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment.
Shazia Ashraf,Shazia Ashraf,Hiroki Kudo,Jia Rao,Atsuo Kikuchi,Eugen Widmeier,Jennifer A. Lawson,Weizhen Tan,Tobias Hermle,Jillian K. Warejko,Shirlee Shril,Merlin Airik,Tilman Jobst-Schwan,Svjetlana Lovric,Daniela A. Braun,Heon Yung Gee,Heon Yung Gee,David Schapiro,Amar J. Majmundar,Carolin E. Sadowski,Werner L. Pabst,Ankana Daga,Amelie T. van der Ven,Johanna Magdalena Schmidt,Boon Chuan Low,Anjali Gupta,Brajendra K. Tripathi,Jenny Wong,Kirk N. Campbell,Kay Metcalfe,Denny Schanze,Tetsuya Niihori,Hiroshi Kaito,Kandai Nozu,Hiroyasu Tsukaguchi,Ryojiro Tanaka,Kiyoshi Hamahira,Yasuko Kobayashi,Yasuko Kobayashi,Takumi Takizawa,Ryo Funayama,Keiko Nakayama,Yoko Aoki,Naonori Kumagai,Kazumoto Iijima,Henry Fehrenbach,Jameela A. Kari,Sherif El Desoky,Sawsan M Jalalah,Radovan Bogdanovic,Natasa Stajic,Hildegard Zappel,Assel Rakhmetova,Sharon Rose Wassmer,Therese Jungraithmayr,Juergen Strehlau,Aravind Selvin Kumar,Arvind Bagga,Neveen A. Soliman,Shrikant M. Mane,Lewis Kaufman,Douglas R. Lowy,Mohamad Aman Jairajpuri,Richard P. Lifton,Richard P. Lifton,York Pei,Martin Zenker,Shigeo Kure,Friedhelm Hildebrandt +68 more
TL;DR: A functional network of RhoA regulation is defined, thereby revealing potential therapeutic targets for nephrotic syndrome and mutations in these genes are mediated by this RLSG module.